Shots:

• ADQ to acquire all the outstanding shares of Amoun Pharmaceutical from Bausch Health for ~$740M. The transaction is expected to close in H1’21
• The divestiture is part of its planned separation of Bausch & Lomb eye-care division
• The sale of Amoun marks important progress to reduce overall Bausch Health debt and plans to prepare for the spinoff of Bausch + Lomb

  Ref: PRNewswire | Image: Financial Post